Shares of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX – Get Free Report) fell 5.8% during mid-day trading on Wednesday . The stock traded as low as $16.95 and last traded at $17.35. 141,373 shares traded hands during trading, an increase of 182% from the average session volume of 50,104 shares. The stock had previously closed at $18.42.
Neoleukin Therapeutics Price Performance
The firm has a market cap of $163.06 million, a PE ratio of -5.58 and a beta of 1.11. The stock has a 50-day moving average price of $19.92 and a 200 day moving average price of $32.51.
About Neoleukin Therapeutics
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
Featured Stories
- Five stocks we like better than Neoleukin Therapeutics
- How to Short Nasdaq: An Easy-to-Follow Guide
- Nebius Group: NVIDIA’s Investment Sparks All-Time Highs
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- SoFi Stock Rallying Strong in the Last 5 Days—What’s Driving It?
- What is the Shanghai Stock Exchange Composite Index?
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
